GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spexis AG (XSWX:SPEX) » Definitions » E10

Spexis AG (XSWX:SPEX) E10 : CHF-3.55 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Spexis AG E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Spexis AG's adjusted earnings per share data for the fiscal year that ended in Dec. 2023 was CHF-0.370. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is CHF-3.55 for the trailing ten years ended in Dec. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-06-10), Spexis AG's current stock price is CHF 0.055. Spexis AG's E10 for the fiscal year that ended in Dec. 2023 was CHF-3.55. Spexis AG's Shiller PE Ratio of today is .


Spexis AG E10 Historical Data

The historical data trend for Spexis AG's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spexis AG E10 Chart

Spexis AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -3.29 -3.55

Spexis AG Semi-Annual Data
Dec13 Dec14 Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -3.29 - -3.55

Competitive Comparison of Spexis AG's E10

For the Biotechnology subindustry, Spexis AG's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spexis AG's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spexis AG's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Spexis AG's Shiller PE Ratio falls into.



Spexis AG E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Spexis AG's adjusted earnings per share data for the fiscal year that ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.37/106.4612*106.4612
=-0.370

Current CPI (Dec. 2023) = 106.4612.

Spexis AG Annual Data

per_share_eps CPI Adj_EPS
201412 -4.565 100.704 -4.826
201512 -5.670 99.386 -6.074
201612 -3.901 99.380 -4.179
201712 -6.320 100.213 -6.714
201812 -5.440 100.906 -5.739
201912 -5.850 101.063 -6.162
202012 -0.140 100.241 -0.149
202112 -0.820 101.776 -0.858
202212 -0.380 104.666 -0.387
202312 -0.370 106.461 -0.370

Add all the adjusted EPS together and divide 10 will get our e10.


Spexis AG  (XSWX:SPEX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Spexis AG E10 Related Terms

Thank you for viewing the detailed overview of Spexis AG's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Spexis AG (XSWX:SPEX) Business Description

Traded in Other Exchanges
Address
Hegenheimermattweg 125, Allschwil, CHE, CH-4123
Spexis AG is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of antibiotics and other specialty pharma products for severe or life-threatening diseases. The company's lead product, murepavadin, is in Phase III development against Pseudomonas aeruginosa - recognized as a critical priority 1 pathogen by World Health Organization. It has one operating segment focusing on the research and development and prospective commercialization of respiratory therapeutics addressing high unmet medical needs.

Spexis AG (XSWX:SPEX) Headlines

No Headlines